Presented (12-73)
U.S. Patient and Trademark Reduction Act of 1996, no persons are required to respond to a collection of information unlass it displays a valid Child covery name.

WER OF A TRADEMARK CO.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS

I hereby revoke any and all previously granted powers of attorney. I hereby appoint Brian S.
Boyer, Reg. No. 52,643, and the attorneys and/or agents associated with Customer No. 45965, to
represent the undersigned before the United States Patent and Trademark Office (USPTO) in
connection with any and all patent applications assigned only to the undersigned according to the
USPTO assignment records or assignment documents attached to this form in accordance with
37 CFR 3.73(b). The undersigned authorizes Brian S. Boyer, and the attorneys or agents
associated with Customer No. 45965 to sign statements in accordance with 37 CFR 3.73(b) on
behalf of the assignee.

Please change the correspondence address and direct all communications to:

Brian S. Bover Customer No. 45965 Technology & Intellectual Property Strategies Group PC P. O. Box 1639 Los Altos, CA 94023

Assignee Name and Address:

CHEMOKINE THERAPEUTICS CORPORATION 6190 Agronomy Road, Suite 405 Vancouver, BC V6T 173 Canada

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filled in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record The individual whose signature and title is supplied below is sutherized to set on behalf of the assignee						
Name	Dr. Hassan Salari					
Signature	Hasa-	Date	08/10/2007			
Title	President and Chief Scientific Officer	Telephone				

13461729_1.DOC 60568-8000/LEGAL13461729.1

STATEMENT UNDER 37 CFR 3.73(b)

		Patent Owner: Christopher R. Tudan, A No./Patent No.: 09/852,424		uk, Lakhdar Arab, Geeta Saxena and Hassan Salari e Date: <u>May 9, 2001</u>	
Entitle	ed: _	CXCR4 Antagonist Treatment of Hen	natopoietic (Cells	
Chen (Name o		e Therapeutics Corporation., a	Corporation (Type of Assignee	1 , e.g., corporation, partnership, university, government agency, etc.)	
states	that	it is:			
1. 🗵	the	assignee of the entire right, title, and i	nterest; or		
2.	an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is%				
in the	pate	nt application/patent identified above b	y virtue of eith	ner:	
A. 🛭	An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel <u>012200</u> , Frame <u>0122</u> , on <u>September 2</u> : <u>2001</u> .				
OR					
В. 🗆	A chain of title from the inventor(s), of the patent application/patent identified above, to the current assigned as shown below:				
	1.	. From: * to: *. The document was rec Reel *, Frame *, or for which a cop		United States Patent and Trademark Office at tached.	
	From: 'to: '. The document was recorded in the United States Patent and Trademark Office at Reel ' Frame', or for which a copy thereof is attached.				
	 From: * to: *. The document was recorded in the United States Patent and Trademark Office at Reel *, Frame *, or for which a copy thereof is attached. 				
	 From: * to: *. The document was recorded in the United States Patent and Trademark Office at Reel *, Frame *, or for which a copy thereof is attached. 				
	[] Additional documents in the chain of title are listed on a supplemental sheet.				
1	Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR 2743, it the assignment is to be recorded in the records of the USPTO. See MPEP 302.08				
The u	ınder	signed (whose title is supplied below) is	s authorized t	o act on behalf of the assignee.	
-		August 13, 2007 Date		Brian S. Boyer Typed or printed name	
-		(650)-293-3350 Telephone number		/Brian S. Boyer/ Signature	
				ATTORNEY OF RECORD	

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the LISPTO be process) an application. Conflicted high to grower dby 36 U.S.C. 122 and 37 CFR 11.4. This collection is estimated to take 12 minutes to complete, including pathering, preparing, and submitting the completed application from to the USPTO. Time with vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Officer, U.S. Department of Commerce, P.O. Box 1450, leavandra, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandra, VA 22313-1450.